Background: Recurrent ovarian cancer (ROC) significantly challenges gynecological oncology due to its poor outcomes. This study assesses the impact of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) on ROC survival rates. Materials and Methods: Conducted at the Medical University of Lublin from April 2011 to November 2022, this retrospective observational study involved 71 patients with histologically confirmed ROC who underwent CRS and subsequent HIPEC. Results: The median overall survival (OS) was 41.1 months, with 3-year and 5-year survival rates post-treatment of 0.50 and 0.33, respectively. Patients undergoing radical surgery for primary ovarian cancer had a median OS of 61.9 months. The key survival-related factors included the Peritoneal Carcinomatosis Index (PCI) score, AGO score, platinum sensitivity, and ECOG status. Conclusions: The key factors enhancing ROC patients’ survival include radical surgery, optimal performance status, platinum sensitivity, a positive AGO score, and a lower PCI. This study highlights the predictive value of the platinum resistance and AGO score in patient outcomes, underlining their role in treatment planning. Further prospective research is needed to confirm these results and improve patient selection for this treatment approach.
背景：复发性卵巢癌（ROC）因其预后不良，对妇科肿瘤学构成重大挑战。本研究评估了肿瘤细胞减灭术（CRS）联合腹腔热灌注化疗（HIPEC）对ROC患者生存率的影响。材料与方法：这项回顾性观察研究于2011年4月至2022年11月在卢布林医科大学进行，纳入了71例经组织学确诊的ROC患者，所有患者均接受了CRS及后续HIPEC治疗。结果：患者中位总生存期（OS）为41.1个月，治疗后3年和5年生存率分别为0.50和0.33。初次卵巢癌接受根治性手术的患者中位OS为61.9个月。关键生存相关因素包括腹膜癌指数（PCI）评分、AGO评分、铂类敏感性和ECOG状态。结论：提高ROC患者生存率的关键因素包括根治性手术、良好的体能状态、铂类敏感性、阳性AGO评分以及较低的PCI。本研究强调了铂类耐药性和AGO评分对患者预后的预测价值，并指出其在治疗规划中的重要作用。未来需要进一步的前瞻性研究来验证这些结果，并优化该治疗方法的患者选择策略。
肿瘤(癌症)患者之家